FDA Approves KalVista's Ekterly As First Oral On-Demand Treatment For Rare Swelling Disease

Why did Tesla stock tumble today? What impact will Trump’s tariff deadline have? How is Elon Musk’s new party affecting Tesla? Why is Apple appealing EU’s $587M fine? How did OPEC+ output hike affect oil prices? Why are investors cautious about Trump’s trade threats? What’s driving Capgemini’s $3.3B acquisition?

FDA Approves KalVista's Ekterly As First Oral On-Demand Treatment For Rare Swelling Disease

benzinga.com/news/fda/25/07/46271482/fda-approves-kalvistas-ekterly-as-first-oral-on-demand-treatment-for-rare-swelling-disease

The U.S. Food and Drug Administration (FDA) on Monday approved KalVista Pharmaceuticals Inc.’s (NASDAQ:KALV) Ekterly (sebetralstat) for acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older.
Ekterly is the first and only oral on-demand…

This story appeared on benzinga.com, 2025-07-07 11:47:09.